Lataa...
A Safety Run-in and Randomized Phase II Study of Cilengitide Combined with Chemoradiation for Newly Diagnosed Glioblastoma (NABTT 0306)
BACKGROUND: Cilengitide is a selective integrin inhibitor that is well tolerated and has demonstrated biological activity in patients with recurrent malignant glioma. The primary objectives of this randomized phase II trial were to determine safety and efficacy of cilengitide when combined with radi...
Tallennettuna:
| Päätekijät: | , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3423527/ https://ncbi.nlm.nih.gov/pubmed/22517399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27585 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|